Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Receivables - Net: 2019-2024

Historic Receivables - Net for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $3.1 million.

  • C4 Therapeutics' Receivables - Net fell 36.74% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 36.74%. This contributed to the annual value of $3.1 million for FY2024, which is 73.71% down from last year.
  • C4 Therapeutics' Receivables - Net amounted to $3.1 million in FY2024, which was down 73.71% from $11.8 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Receivables - Net registered a high of $11.8 million during FY2023, and its lowest value of $1.5 million during FY2022.
  • In the last 3 years, C4 Therapeutics' Receivables - Net had a median value of $3.1 million in 2024 and averaged $5.5 million.
  • Per our database at Business Quant, C4 Therapeutics' Receivables - Net tumbled by 74.23% in 2022 and then skyrocketed by 701.02% in 2023.
  • C4 Therapeutics' Receivables - Net (Yearly) stood at $4.5 million in 2020, then rose by 27.48% to $5.7 million in 2021, then slumped by 74.23% to $1.5 million in 2022, then surged by 701.02% to $11.8 million in 2023, then plummeted by 73.71% to $3.1 million in 2024.